MAPT and dementia: In conclusion, this study demonstrates P-tau181P is a fundamental component of the AD biomarker panel and the combined assessment of Aβ1–42, T-tau, and P-tau181P renders, to present date, the highest diagnostic power to discriminate between AD and non-AD dementias.